Board member José Willemse is a member of the advisory board of NEOLVIER, an EU project.
Last February she spoke at the annual meeting about the patient perspective in research.
NEOLIVER is a Horizon Europe research and innovation project developing world’s first autologous bioprinted liver which will be validated in large animal models. Our ultimate goal is to produce dense, vascularized bioprinted liver constructs suitable for clinical use as an Advance Therapy Medicinal Product (ATMP).
NEOLIVER will tackle key technological challenges and barriers in whole organ engineering by merging two bioprinting technologies and exploring different innovation routes.